Histogen Inc. is a clinical-stage company that develops biologic products using a proprietary hypoxia-generated growth factor technology platform to treat various medical conditions, including articular cartilage defects and spinal disc repair. Their product candidates also include CTS-2090 and CTS-2096, which target inflammasome activation and intervene in various inflammation-mediated diseases. The company was founded in 2007 and is headquartered in San Diego, California.